Introduction
Cancers not completely eradicated by surgery or radiation (localized therapy) may escape control by chemotherapy (systemic therapy) because some cancer cells, especially those resistant to apoptosis, survive treatment (1, 2) . For example, prostate cancer that recurs after potentially curative therapy, or that presents in an advanced stage, is palliated with androgen-deprivation therapy. Within several years most recur as androgen-independent, metastatic disease that leads to death. Recently, chemotherapy regimens have been developed that allow palliation in most patients. While such treatments may lead to re-remissions of one year or more, they have not proven to increase survival (3) (4) (5) .
Chemotherapeutic resistance usually arises due to overexpression of anti-apoptotic proteins such as Bcl-2 and Bcl-xL (2, (6) (7) (8) . Bcl-2 is regarded as one of the most important proteins protecting cancer cells from apoptosis and, to date, may be the most highly studied member of the Bcl-2 family. However, in an examination of 60 different cell lines from the National Cancer Institute, Bcl-xL was shown to provide equivalent or greater protection against cytotoxic agents than Bcl-2. Higher levels of Bcl-xL correlated with decreased cellular sensitivity towards a variety of chemotherapeutic reagents; there was no such correlation for Bcl-2 (6) . Other studies have shown that high levels of Bcl-xL contributed to increased risk of metastasis in breast cancer (9) and protected cancer cells from chemotherapeutic agents (10, 11 ).
In addition, cancer cells were sensitized to various apoptosis inducing agents if Bcl-xL levels were decreased (12, 13) .
Bcl-xL and Bcl-xS are splice variants produced by alternative splicing of Bcl-x premRNA (14) . While Bcl-xL is anti-apoptotic, Bcl-xS has been shown to induce cell death (15, 16) and sensitize cancer cells to chemotherapeutic agents (17) (18) (19) (20) . Bcl-xS inhibits the antiapoptotic effects of Bcl-xL and Bcl-2, possibly by forming heteroduplexes with these proteins (21) and/or by acting as a dominant negative gene product (22) . Decreasing Bcl-xL and increasing Bcl-xS levels may initiate pro-apoptotic events through various cellular mechanisms that, alone or in synergy with the action of antineoplastic agents, lead to cell death.
We have shown previously that a 2'-O-methyl-oligoribonucleoside-phosphorothioate (5'Bcl-x AS) targeted to the downstream alternative 5' splice site in exon 2 of Bcl-x premRNA shifted splicing from the Bcl-xL to Bcl-xS splice variants; this treatment decreased the levels of Bcl-xL and increased the levels of Bcl-xS proteins (23) . The shift in splicing induced cell death in oligonucleotide treated PC3 prostate cancer cells, and to a lesser extent in MCF7 breast cancer cells. In A549 lung epithelial cells, a similar treatment alone was ineffective; cell death resulted only from co-administration of radiation or cisplatin (24) . These findings prompted us to investigate the differences in cellular responses as a result of oligonucleotideinduced modification of Bcl-x pre-mRNA splicing. We found that the endogenous level of Bclx is the main factor that determines the extent of cell death induced by 5'Bcl-x AS. Treatment of PC3 and MCF7 cells (two cell lines that express different levels of Bcl-xL) with 5'Bcl-x AS sensitized both cell lines to various chemotherapeutic agents and radiation and increased cell death at lower doses of these agents. Finally, prostate cancer expressed higher levels of Bcl-xL protein than benign prostate. These results suggest that 5'Bcl-x AS treatment may augment the effectiveness of radiation and chemotherapy for prostate cancer.
Experimental Procedures
Cells Lines and Prostate Tissue Samples. The treated human cancer cell lines were from prostate (PC3, DU145), breast (MCF7, MDA-MB-231, BT-549, Hs578T) and cervical (HeLa) cancers. They included four p53 mutant cells (PC3, DU145, MDA-MB-231, Hs578T) (25) (26) (27) (28) and three p53 positive cells (MCF7, BT549, HeLa) (25, (28) (29) (30) . Among the breast cancer cell lines, two were ER negative (MDA-MB-231, Hs578T) (28) and two were ER positive (MCF7, BT549) (28, 29) . PC3 and DU145 were androgen-insensitive prostate cancer cell lines. All cell lines were originally from the ATCC and grown in a humidified incubator with 5% CO 2 at In radiation experiments, cells were replated in 10 cm plates 24 hrs after oligonucleotide treatment. After overnight culture, cells were irradiated using a 60 Co γ-irradiator at doses indicated in Fig. 7 . The numbers of re-plated and radiated cells were: control PC3 cells, 500 at 0-2 Gy, 1000 at 4 Gy; 5Bcl-x AS transfected PC3 cells: 500 at 0 Gy, 1000 at 1 and 2 Gy, 2000 at 4 Gy; control MCF7 cells, 1000 at 0-2Gy, 2000 at 4 Gy; 5'Bcl-x AS transfected MCF7 cells: colonies stained and counted on day 10 of culture (see below), and the % viability (or replating efficiencies) was calculated.
RNA isolation and reverse transcription-PCR (RT-PCR).
These procedures were carried out as previously described (23) . Briefly, 48 hrs after oligonucleotide transfection, cells were lysed in 1 ml of TRI-reagent (MRC, Cincinnati, OH) and total RNA was isolated. RT-PCR was (Fig. 3) .
To further address this issue, an examination of the levels of Bcl-xL mRNA was carried out by RPA. The results showed that the levels of Bcl-xL were highest in PC3 cells, followed by MDA 231, DU145, Hs578T, MCF7, BT549 and lowest in HeLa cells (Fig. 4A, B) . Analysis of Bcl-xL protein by immunoblotting with anti Bcl-xL antibody established the same rank order of Bcl-xL expression levels (Fig. 4C, D) . There was a high degree of correlation (p-value of < 0.0001 and r 2 =0.9601, by Pearson correlation) between the levels of Bcl-xL protein in untreated cell lines and death of 5'Bcl-x AS treated cells, indicating that cells containing higher levels of Bcl-xL were more susceptible to 5'Bcl-x AS oligonucleotide treatment.
This counterintuitive result, that increased expression of anti-apoptotic Bcl-xL at the same time facilitates cell death of 5'Bcl-x AS treated cells, is best explained by the data illustrated in Figure 5A , B. The seven different cell lines were treated with 5'Bcl-x AS at concentrations indicated in Figure 2A that resulted in 50-60% shift in Bcl-x pre-mRNA splicing. In spite of the fact that the relative amounts of Bcl-xL/xS mRNAs were the same in all cell lines (i.e. the ratio of Bcl-xL to -xS was approximately 50-60%), RPAs of total RNA with a Bcl-xS specific probe showed that the absolute levels of Bcl-xS mRNA varied substantially ( PC3 cells were found to be more sensitive to the combined oligonucleotide-radiation treatment. Cell viability was reduced close to 2-fold even at low doses (0.01 µM oligonucleotide and 1 Gy radiation). Under these conditions viability of the cells was lower than that of control cells irradiated at 2 Gy dose (Fig. 7B) . As the radiation dose increased, the effects of the shift in Bcl-xL/Bcl-xS splicing became less pronounced; at 4 Gy there was no further sensitization, presumably because the radiation alone induced massive cell death. Overexpression of the mdr1 gene, which codes for P-glycoprotein, is the principal mechanism of the chemoresistance for these cells (38) (39) (40) (41) . Treatment of MCF7/ADR cells with 5'Bcl-x AS oligonucleotides resulted in a dose-dependent shift in splicing from Bcl-xL to Bcl-xS (Fig. 8A) .
5'Bcl-x AS induces cell death in the multi
The EC 50 of 5'Bcl-x AS (0.08 µM) was comparable to its EC 50 in PC3 cells (0.08 µM) and 5-fold lower than in parent MCF7 cells (0.4 µM). This effect appears to be due to increased uptake of the oligonucleotide-DMRIE-C complex into the nuclei (data not shown, see Discussion). The shift in splicing led to a dose dependent decrease in the viability of the MCF7/ADR cells ( In order to examine this observation in more detail, the level of Bcl-xL protein in MCF7/ADR cells was determined and plotted versus cell viability and compared to the other cell lines studied. The level of Bcl-xL was similar to that of the parent MCF7 cells (Fig. 8C) . The decrease in cell viability was similar and agreed with the results obtained for other cell lines (Fig.   8C , p< 0 .0001 and r 2 =0.9480 by Pearson correlation). Thus, in spite of apparent changes in the oligonucleotide uptake resulting in increased sensitivity of Bcl-xL/xS splicing to oligonucleotide treatment, the decrease in cell viability remained unchanged suggesting that it depended only on the endogenous level of Bcl-x pre-mRNA as reflected in the levels of Bcl-xL protein.
High expression of Bcl-xL in prostate cancer. Since the androgen-insensitive prostate cancer cell lines, PC3 and DU145, had among the highest levels of Bcl-xL, we tested if clinical specimens of prostate cancer recurrent after androgen deprivation therapy exhibited increased expression of this gene. Immunoblot analysis of prostate cancer and benign prostate samples showed significant differences in the levels of Bcl-xL between the two groups (p= 0.0012, 2-tailed t-test; Fig. 9 ). This suggests that Bcl-xL may play a role in the progression of prostate cancer and that modulation of its expression may be a means of controlling that progression.
Discussion
Several recent studies showed that antisense oligonucleotide-mediated downregulation of expression of Bcl-xL and other anti-apoptotic genes enhanced apoptosis with and without additional treatment with chemotherapeutic drugs (13, 18, (42) (43) (44) (45) (46) (47) . In these approaches, the higher (23) . Thus, it appears that high expression of Bcl-xS is able to override several different anti-apoptotic pathways. These findings may be exploited as a prognostic tool to identify tumors that are most likely to benefit from 5'Bcl-x AS treatment. It is therefore encouraging that prostate cancer has higher levels of Bcl-xL compared with benign prostate (Fig. 9) or lower grade tumors (50) . Furthermore, 5'Bcl-x AS should be quite specific as a drug since non-cancerous cells, that typically express low levels of Bcl-xL, should be relatively resistant to the treatment. While data presented in this paper suggest that the endogenous level of Bcl-xL is a major factor in several cell lines, the role of other factors in different cell lines cannot be ruled out. For example, cells may degrade the oligonucleotide faster, have different rates of mRNA turnover, varying expression levels of other apoptotic genes (such as caspases), or varying levels of proteins in pathways that interact with Bcl-xL and/or Bcl-xS function (e.g. PKC and MEK-dependent pathways that regulate Bcl-xL expression (51, 52) and JNK which phosphorylates Bcl-xL (49)).
The oligonucleotide-induced shift in splicing alone was able to cause significant cell The finding that cells that express higher levels of Bcl-xL were more sensitive to 5'Bclx AS induced cell death, suggests that cancers that express high levels of Bcl-xL may benefit from treatment with the oligonucleotide. In particular, the effects of 5'Bcl-x AS combined with chemotherapeutic agents may be translated to clinical prostate cancer since recurrent prostate cancer expresses high levels of Bcl-xL. The potential combination of 5'Bcl-x AS with standard anti-cancer treatments warrants further exploration, especially in recurrent prostate cancer. 
